Investigation of Hippo pathway-related prognostic lncRNAs and molecular subtypes in liver hepatocellular carcinoma

por Su, Qiongfei, Hua, Fengyang, Xiao, Wanying, Liu, Baoqiu, Wang, Dongxia, Qin, Xintian
Publicado 2023

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial

por Yang, Yunpeng, Min, Jie, Yang, Nong, Yu, Qitao, Cheng, Ying, Zhao, Yanqiu, Li, Manxiang, Chen, Hong, Ren, Shou’an, Zhou, Jianying, Zhuang, Wu, Qin, Xintian, Cao, Lejie, Yu, Yan, Zhang, Jian, He, Jianxing, Feng, Jifeng, Yu, Hao, Zhang, Li, Fang, Wenfeng
Publicado 2023

Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study

por Shi, Yuankai, Qin, Xintian, Peng, Xingchen, Zeng, Aiping, Li, Jingao, Chen, Chuanben, Qiu, Sufang, Pan, Suming, Zheng, Yulong, Cai, Jing, Chen, Xiaopin, Qu, Shenhong, Lin, Lizhu, Huang, Jianli, Wu, Hui, Lu, Ying, Wang, Wei, Hu, Changlu, He, Xia, Yu, Zhonghua, Liu, Xiaojian, Xie, Bo, Liu, Anwen, Hu, Guangyuan, Jing, Shanghua, Zhang, Qingyuan, Guo, Renhua, Li, Qi, Hong, Jinsheng, Jin, Feng, Meng, Juan, Shi, Jianhua, Wang, Peiguo, Cui, Jiuwei, Yang, Kunyu, Zhang, Xuebang, Li, Xiaojiang, Shen, Liangfang, He, Yuxiang, Zhai, Limin, Sun, Xiuhua, Ge, Junyou, Qing, Yan, Zong, Dekang
Publicado 2022